All posts by imreal

MotherToBaby Launches First Lupus in Pregnancy Research Study


“Lupus can raise the risk of pregnancy complications, so it’s important for both the mom and her developing baby that this condition be well-managed during pregnancy.” – Christina Chambers, PhD, MPH

Recruitment is underway for a groundbreaking new study on the treatment of lupus during pregnancy. The observational research, led by world-renowned UC San Diego epidemiologist Christina Chambers, PhD, MPH, is the first of its kind for the non-profit MotherToBaby, a CDC-recommended organization that provides evidence-based information on medications, diseases, vaccines, herbal supplements and more during pregnancy and breastfeeding.

The study will recruit 400 pregnant people over a five-year period to evaluate use of the lupus drug Benlysta® (belimumab) in pregnancy. Benlysta® is used to treat the most common type of lupus, systemic lupus erythematosus (SLE), as well as lupus nephritis. Currently, there is limited information on the drug’s use in pregnancy.

The study will be MotherToBaby’s first to focus on a treatment specifically for lupus, and participants will be enrolled into the MotherToBaby Pregnancy Studies research program. Chambers, who is the lead investigator for MotherToBaby Pregnancy Studies, Co-Director of the Center for Better Beginnings, and Chief of the Environmental Science and Health Division in the UC San Diego Department of Pediatrics, noted that, “lupus can raise the risk of pregnancy complications, so it’s important for both the mom and her developing baby that this condition be well-managed during pregnancy. So, when treatments for lupus like belimumab are available, we want to do our best to gather information about those pregnancies where this medication has been used.”

The study is enrolling pregnant and recently pregnant people with exposure to Benlysta® and will provide critical information on the use of this medication during pregnancy. Participants will not be asked to change any part of their health care routine, including medications, nor will they be asked to travel.

More about MotherToBaby Pregnancy Studies

MotherToBaby Pregnancy Studies are conducted by the non-profit Organization of Teratology Information Specialists (OTIS) and coordinated at the Center for Better Beginnings at UC San Diego. OTIS is a professional scientific society made up of individuals engaged in assessing and evaluating risks to pregnancy and breastfeeding from environmental exposures. Members include, but are not limited to, specialists in the fields of obstetrics and gynecology, pediatrics, genetics, dysmorphology, perinatal epidemiology, teratology, behavioral teratology, pharmacy, genetic counseling, nursing, midwifery, maternal and child health, public health, and include experts that provide MotherToBaby services and researchers that conduct MotherToBaby Pregnancy Studies.

MotherToBaby is a suggested resource by many federal agencies including the Centers for Disease Control and Prevention (CDC). MotherToBaby is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $6,000,000 with zero percentage financed with non-governmental sources. The contents of this release are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS or the U.S. Government. To learn more about MotherToBaby and OTIS, please visit MotherToBaby.org.

Media Contact: Nicole Chavez, nchavez@mothertobaby.org, 619-368-3259

Share article on social media or email:

Energage Names Chapters Health System A Winner of the 2023 Top Workplaces USA Award


Chapters Health System

“It is a meaningful honor to be recognized nationally based on the feedback of our team members,” said Andrew Molosky, MBA, FACHE, CHPCA, president and chief executive officer for Chapters Health.

Chapters Health System, one of the nation’s premier not-for-profit, community-based healthcare organizations headquartered in Temple Terrace, announced today its naming as a winner of the 2023 Top Workplaces USA award. It was named to the list based solely on employee feedback gathered through a third-party survey administered by employee engagement technology partner Energage LLC. The anonymous survey uniquely measures 15 culture drivers that are critical to the success of any organization: including alignment, execution and connection, just to name a few.

“It is a meaningful honor to be recognized nationally based on the feedback of our team members,” said Andrew Molosky, MBA, FACHE, CHPCA, president and chief executive officer for Chapters Health. “There is a great amount of pride in stating we have a strong culture based on the mantra that our positions are viewed as more than jobs…they are our mission. People come to Chapters Health to be part of an organization performing meaningful and impactful work 24/7/365 in taking care of patients and families with or affected by advanced illness. Every day our team members impact lives across a wide continuum of care. Chapters Health is truly a top workplace.”

“Companies need to authentically represent their brand to job-seekers,” said Eric Rubino, Energage CEO. “The employee experience needs to be on the mission-critical list. Leaders who embrace a people-first culture will benefit greatly. By giving employees a voice and showcasing your authentic culture through employer branding, organizations can attract those job seekers who complement their culture. Culture drives performance.”

About Chapters Health System

As a progressive leader and premier healthcare organization, Chapters Health System is dedicated to delivering innovative care throughout chronic illness progression and beyond. Since 1983 as a community-based, not-for-profit organization, Chapters Health has provided choices, education, and guidance through its managed affiliates. All offerings are provided in order to improve the patient/family experience well in advance of end-of-life needs. In 2022, Chapters Health earned certified status for information security from HITRUST; for the fifth consecutive year was recognized as a great workplace in the Aging Services category by the independent analysts at the Great Place to Work® Institute; and in 2021 was named a Top Workplace by the Tampa Bay Times. To learn more, visit http://www.chaptershealth.org, like us on Facebook or follow us on Twitter and LinkedIn.

About Energage

Energage is a purpose-driven company that helps organizations turn employee feedback into useful business intelligence and credible employer recognition through Top Workplaces. Built on 14 years of cultural research and the results from 23 million employees surveyed across more than 70,000 organizations,  Energage delivers the most accurate competitive benchmark available. With access to a unique combination of patented analytic tools and expert guidance, Energage customers lead the competition with an engaged workforce and an opportunity to gain recognition for their people-first approach to culture. For more information or to nominate your organization, visit energage.com [energage.com __title__ energage.com] or topworkplaces.com [topworkplaces.com __title__ topworkplaces.com].

                                                                                             ###

Share article on social media or email:



Mays Cancer Center led studies of innovative breast cancer drug that recently gained FDA approval


“The drug’s approval means it serves as another option of treatment for our patients with advanced or metastatic breast cancer.” — Virginia Kaklamani, MD, Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center

The Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, was the lead site for a study evaluating Phase I and Phase III clinical trials for elacestrant, a treatment for postmenopausal women and adult men with ER+/HER2- advanced or metastatic breast cancer. The U.S. Food and Drug Administration on Jan. 27 announced it approved the novel drug therapy.

The first endocrine drug therapy approved since 2002, elacestrant is also the first drug therapy for patients with tumors that are estrogen receptor 1 (ESR1)-mutated. ESR1 mutations are present in up to 40% of ER+/HER2- advanced or metastatic breast cancers, and they are known to resist standard endocrine therapy, making them difficult to treat.

Estrogen receptor-positive (ER+) cells are breast cancer cells that test positive for estrogen receptors, which means estrogen is fueling the growth of the cancer. HER2 stands for human epidermal growth factor receptor 2, a protein that appears on the surface of some breast cancer cells. HER2-negative breast cancers have little or no HER2 protein.

“As a member of the trial’s steering committee and one of the principal investigators, I was excited to hear the FDA’s approval of elacestrant,” said Virginia Kaklamani, MD, leader of the Breast Oncology Program at the Mays Cancer Center and professor of medicine at UT Health San Antonio. “We were involved in the drug’s development during the Phase I and Phase III clinical trials, which showed positive results compared to the standard of care. The drug’s approval means it serves as another option of treatment for our patients with advanced or metastatic breast cancer.”

The randomized, open-label study included 478 patients with ER-positive/HER2-negative metastatic breast cancer, receiving either elacestrant or standard of care.

Elacestrant was under evaluation in EMERALD, a class of anticancer drugs called selective estrogen receptor degraders (SERDs). The clinical trial compared outcomes from the standard of care endocrine therapy versus elacestrant. The trial showed that elascestrant improved outcomes in patients.

The Mays Cancer Center is one of only four National Cancer Institute (NCI)-designated Cancer Centers in Texas. Through its mission to reduce the burden of cancer in San Antonio, South Texas and beyond, the Mays Cancer Center provides leading-edge care, driving innovative cancer research and educating the next generation of clinicians to end cancer.

“The FDA approval of elacestrant for the treatment of metastatic breast cancer is a strong testament to the commitment of the Mays Cancer Center toward the alleviation of cancer burden through innovative research and clinical trials,” Patrick Sung, DPhil, interim executive director of Mays Cancer Center and professor of biochemistry and structural biology. “Our congratulations to Dr. Virginia Kaklamani and her colleagues for this monumental achievement.”

# # #

The Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, is one of only four National Cancer Institute-designated Cancer Centers in Texas. The Mays Cancer Center provides leading-edge cancer care, propels innovative cancer research and educates the next generation of leaders to end cancer in South Texas. To learn more, visit http://www.UTHealthSAMDAnderson.org.

Stay connected with the Mays Cancer Center on Facebook, Twitter, LinkedIn, Instagram and YouTube.

The University of Texas Health Science Center at San Antonio (UT Health San Antonio), a primary driver for San Antonio’s $44.1 billion health care and biosciences sector, is the largest research institution in South Texas with an annual research portfolio of $360 million. Driving substantial economic impact with its six professional schools, a diverse workforce of 7,900, an annual operating budget of $1.08 billion and clinical practices that provide 2.6 million patient visits each year, UT Health San Antonio plans to add more than 1,500 higher-wage jobs over the next five years to serve San Antonio, Bexar County and South Texas. To learn about the many ways “We make lives better®,” visit UTHealthSA.org.

Share article on social media or email:



Cirtec Medical Acquires QMD™ Precision Components Business


Cirtec Medical Corporation, a strategic outsourcing partner of complex medical devices including minimally invasive and active implantable devices, has acquired QMD’s Precision Components business which specializes in the development and manufacturing of silicone, polyisoprene and other custom elastomeric components, tubing, and subassemblies.

“This acquisition is a natural fit for us and will open new doors for customers through advanced expertise in medical silicone molding and extrusion,” stated Brian Highley, Cirtec CEO. “From materials science and mold development through manufacturing and assembly, QMD Precision Components will enable Cirtec to provide customers with new and powerful capabilities as a full-service outsource partner.”

“The acquisition will also strengthen Cirtec’s platform for growth in existing markets such as active implantables, interventional, and minimally invasive surgical devices,” said Highley.

Precision Components will integrate within the Cirtec brand, offering comprehensive, integrated solutions based on decades of silicone experience. The business consists of Centers of Excellence in Sturtevant, Wisconsin and Rock Hill, South Carolina. Engineering and manufacturing capabilities will remain at the facilities, along with current leadership.

Mauricio Arellano, QMD CEO, commented, “The combination of Cirtec and QMD Precision Components creates one of the world’s most comprehensive set of capabilities in Medical Device Outsourcing today, translating into extremely exciting opportunities for the benefit of our customers, our associates and most importantly, the patients we all have the privilege of serving.”

About Cirtec Medical

Cirtec Medical is a vertically integrated, full-service outsource partner providing end-to-end product design, development, and manufacturing of Class III and II medical devices and components. We specialize in today’s most advanced product technologies including, neuromodulation, implantable drug delivery, cardiac rhythm management, ventricular assist and interventional devices and delivery systems. Cirtec has a global footprint with facilities in Brooklyn Park, MN; Chandler, AZ; El Coyol, Costa Rica; Enfield, CT; Los Gatos, CA; Lowell, MA; Birkenfeld, Germany; Sturtevant, WI; and Rock Hill, SC.

Share article on social media or email:

Healthie Named to the New York Digital Health 100


News Image

“Our goal is to make the healthcare experience better for both patients and providers. By facilitating more collaborative care, enabling data sharing, and powering seamless access to the care team, we know we can change the future of healthcare, one provider at a time.” – Erica Jain, CEO of Healthie

Healthie today announced that it has been named to the New York Digital Health 100 (DH100), a recognition that highlights the most exciting and innovative startups in the New York region.http://dhny.coDigital Health New York (DHNY) publishes the annual list as part of the New York Healthcare Innovation Report, a comprehensive analysis that takes an in-depth look at the data, trends and people that have propelled New York to become the capital of healthcare innovation.

“Our goal is to make the healthcare experience better for both patients and providers. By facilitating more collaborative care, enabling data sharing, and powering seamless access to the care team, we know we can change the future of healthcare, one provider at a time,” said Erica Jain, co-founder and CEO of Healthie. “We are proud to be included in this impressive group of New York-based companies united by a mission to improve the healthcare industry.”

“In 2023, the New York Digital Health 100 includes an incredibly diverse, innovative and forward-thinking set of companies and leaders that are making an impact on the future of healthcare,” said Bunny Ellerin, Co-Founder and CEO, DHNY. “On behalf of the entire New York healthcare ecosystem, we are delighted to spotlight these organizations, support their growth and applaud them for their meaningful contributions to improving healthcare.”

Now in its 4th year, the DH100 had double the number of applicants compared to 2022. With this explosive growth, the scope of the list greatly expanded, and now represents 35 new companies; counts 12 unicorns among its ranks; has 23 organizations that are led by female CEOs; and 37 of the companies on the list raised $1.6B in 2022.

Healthie enables over 2,000 health and wellness organizations to offer virtual-first, digitally-enabled care and build long-term relationships with healthcare clients. Healthie empowers providers to offer the virtual services consumers demand, providing the feature sets to build back-office operations and deliver a modern patient experience. Sitting at the center of provider and customer interaction, Healthie houses business, operational, financial, and health information for customers and powers a better experience for thousands of patients daily.

To learn more about Healthie, please visit https://www.gethealthie.com.

To download a copy of the New York Healthcare Innovation Report, please click here.

ABOUT HEALTHIE

Healthie offers infrastructure for next-generation digital health organizations that provide virtual-first care. Healthie’s API-first and fully brandable suite of solutions (Scheduling, EMR, Client Engagement) enables healthcare builders to launch and scale best-in-class experiences for their members. The company also offers a built-in marketplace of business and clinical integrations used by their organizations.

Healthie is HIPAA Compliant and SOC-2 Certified. Healthie’s customers include prominent digital health companies that have raised $2B+ in venture capital and range from 5-person startups to multi-billion-dollar companies. In partnership with Healthie, they care for patients across the full spectrum — from preventative health and wellness to complex chronic care management, for millions of patients. For more information, visit http://www.gethealthie.com

About Digital Health New York (DHNY)

Digital Health New York (DHNY) is the premier network of CEOs, entrepreneurs, investors, payers and providers driving New York’s healthcare ecosystem. DHNY works to increase the visibility of New York as a leader in healthcare innovation, showcases the organizations and leaders curating the future of healthcare, and brings people together to share ideas, spark new directions and create success. For more information, visit http://www.dhny.cohttp://www.dhny.co.

Share article on social media or email:

Nominate a Top Emergency, Trauma or Transport Nurse for a 2023 BCEN Distinguished Award


News Image

“We encourage nurses, leaders and employers to nominate a deserving emergency, trauma or transport nurse for one of BCEN’s Distinguished Awards,” said BCEN CEO Janie Schumaker.

Nominations are now being accepted for the 2023 BCEN Distinguished Awards, which will honor top board certified RNs for their commitment to excellence in five emergency nursing specialties: adult/mixed emergency, pediatric emergency, flight, critical care ground transport, and trauma.

The annual Distinguished Awards are sponsored by the Board of Certification for Emergency Nursing (BCEN). Approximately 50,000 RNs worldwide hold a BCEN nursing specialty credential, with over 40,000 holding the Certified Emergency Nurse (CEN).

BCEN’s Distinguished Awards are open to RNs across the United States and around the world who hold any of BCEN’s five nursing specialty credentials. Nominees can be bedside nurses and/or serving in nurse leader, educator, professional development, administrator, research or military roles. Nurses may self-nominate or be nominated by a colleague, a supervisor, or their organization.

“Recognizing the excellence and extraordinary commitment of board certified nurses is one of the most important things we do,” said BCEN CEO Janie Schumaker, MBA, BSN, RN, CEN, CENP, CPHQ, FABC. “We encourage nurses, leaders and employers to nominate a deserving emergency, trauma or transport nurse for one of BCEN’s Distinguished Awards.”

Nominations are being accepted through March 15, 2023, for the following awards:


  • 2023 Distinguished CEN Award (adult/mixed emergency)
  • 2023 Distinguished CPEN Award (pediatric emergency)
  • 2023 Distinguished CFRN Award (flight)
  • 2023 Distinguished CTRN Award (critical care ground transport)
  • 2023 Distinguished TCRN Award (trauma)

Winners will receive a one-year all-access pass to the award-winning BCEN Learn continuing education platform (valued at $2,500), including the entire library of high-interactivity advanced CE courses plus all games, practice exams and BCEN Learn Live on-demand conference proceedings.

Visit https://bcen.org/distinguished-award-nominations/ to submit your nominee by Wednesday, March 15, 2023, at 11:59 p.m. CDT.

The 2023 BCEN Distinguished Award honorees will be selected on the basis of: (1) their commitment to specialty certified clinical excellence and professionalism in their own nursing practice or role, and (2) their leadership and innovation in supporting and advancing nursing specialty certification and specialty certified nursing care. Visit the BCEN awards page for complete details and eligibility criteria.

The nomination window for the 2023 BCEN National Certification Champion Award, which recognizes organizations for their commitment to nursing excellence across the emergency spectrum, opens June 1.

About BCEN

Founded in 1980, the independent, not-for-profit Board of Certification for Emergency Nursing (BCEN®) offers robust certification programs fostering empowered nurses across the emergency spectrum who contribute noticeably to patient care, safety and outcomes. Nearly 59,000 BCEN board certifications are held by registered nurses (RNs) who specialize in emergency, flight, pediatric emergency, critical care ground transport, and trauma nursing. BCEN offers the Certified Emergency Nurse (CEN®), Certified Flight Registered Nurse (CFRN®), Certified Pediatric Emergency Nurse (CPEN®), Certified Transport Registered Nurse (CTRN®) and Trauma Certified Registered Nurse (TCRN®) certifications. Through the award-winning BCEN Learn continuing education platform and the BCEN Learn Live conferences, BCEN supports advanced emergency nursing lifelong learning. Learn more at bcen.org. Follow BCEN on Facebook, LinkedIn and Instagram.

# # #

EDITOR’s NOTE: High resolution images of the awards icons are available by request.

Share article on social media or email:

Body Expert Dr. Alton Ingram Joins Exclusive Haute Beauty Network


News Image

At Ingram Cosmetic Surgery we specialize in Breast Augmentation, Breast Lift, Tummy Tuck, Facelift, Blepharoplasty, and Mommy-Makeover Surgery.

Dr. Alton Ingram is a Top Rated double board-certified cosmetic surgeon in Nashville, Tennessee. He focuses only on surgical procedures and only on those procedures in which he has multiple fellowship training.

Dr. Ingram is board certified in Cosmetic Surgery and Facial Cosmetic Surgery. He is a graduate of Yale University and the University of Texas Southwestern Medical Center, the top-ranked plastic surgery residency in the United States. He completed fellowships with Professor Ivo Pitanguy, the Brazilian surgeon who operated on Sophia Lauren, Jacqueline Kennedy Onassis, and Racquel Welch and is the father of aesthetic plastic surgery, as well as at the University of Paris, with Dr. Patrick Maxwell at Baptist Hospital in Nashville, and at Mount Sinai Medical Center in Miami Beach.

Ingram Cosmetic Surgery is a luxury, patient-centered surgical facility in Nashville and Brentwood, Tennessee. We focus solely on cosmetic surgery of the face, breast, and body. We only perform surgical procedures and do not offer non-surgical options such as injectables and skin treatments so we can give our patients the most dramatic and long-lasting results possible.

With your safety as our number-one priority (Dr. Ingram is a co-founder of Cosmetic Surgery Patient Safety Certification and frequently lectures on patient safety at national and international meetings), Dr. Ingram will work with you individually to provide a customized treatment plan and will see you at each follow-up visit to ensure you received the best care and results possible.

Dr. Ingram is a trustee of the American Board of Cosmetic Surgery, a fellow of the American Academy of Cosmetic Surgery, a Section Editor of The American Journal of Cosmetic Surgery, and a member of the Editorial Board of Modern Research in Plastic and Reconstructive Surgery. He is an examiner for the written and oral boards in cosmetic surgery and facial cosmetic surgery and the only plastic surgeon on staff at Nashville General Hospital, where he provides free reconstructive surgery to those who need it most.

At Ingram Cosmetic Surgery we specialize in Breast Augmentation, Breast Lift, Tummy Tuck, Facelift, Blepharoplasty, and Mommy-Makeover Surgery. We limit our surgical repertoire in order to focus on what we do best!

Learn more about Dr. Alton Ingram by visiting:

https://hauteliving.com/hautebeauty/member/dr-alton-ingram/

ABOUT HAUTE BEAUTY NETWORK:

Haute Beauty is affiliated with the luxury lifestyle publication Haute Living. As a section of Haute Living magazine, Haute Beauty covers the latest advancements in beauty and wellness, providing readers with expert advice on aesthetic and reconstructive treatments through its network of acclaimed doctors and beauty experts.

For more about Haute Beauty, visit https://hauteliving.com/hautebeauty/

Share article on social media or email:

Los Angeles Robotic Hip and Knee Replacement Surgeon, Dr. Farzin Kabaei, Recognized as a 2023 Top Patient Rated Doctor


News Image

“It is such an honor to be recognized with this distinguished award from Find Local Doctors,” says Dr. Kabaei.

At Robotic Hip and Knee Replacement LA, Dr. Farzin Kabaei and his team use a multi-disciplinary approach to knee, hip and shoulder treatments at his state-of-the-art medical center in Los Angeles, California. He has been selected by Find Local Doctors for this honor as a result of his many five-star ratings and excellent reviews from satisfied patients across multiple online sources. Find Local Doctors is a user-friendly online directory that helps consumers connect with skilled physicians in their area. In many of Dr. Kabaei’s reviews, patients have commented on his surgical skill and the top-notch professionalism that he provides.

Dr. Kabaei is a board-certified orthopedic surgeon, specializing in hip, knee and shoulder joint disorders and offers advanced treatment options at his clinic. Dr. Kabaei’s credentials and experience in this specialized field have made him one of the top knee and hip surgeons in the country. Patients from around the globe travel to see Dr. Farzin Kabaei for cutting-edge procedures using his expert knowledge of the Mako™ robotic joint replacement system. His experience and deep understanding of the robotic system’s capabilities, make him a highly sought-after surgeon, allowing patients to receive same-day knee and hip joint replacement surgery. Dr. Kabaei is a renowned expert in robotic hip and knee replacement surgery, but he also offers innovative treatments for knee, hip and shoulder issues, including combining regenerative medicine, interventional treatments and surgical options.

“It is such an honor to be recognized with this distinguished award from Find Local Doctors,” says Dr. Kabaei.

More about Dr. Farzin Kabaei:

Dr. Kabaei received his undergraduate degree in neuroscience from UCLA and his medical degree from Albert Einstein College of Medicine. His orthopedic residency training was completed at Montefiore/Einstein Medical Center with fellowship training at Cedars-Sinai Medical Center in Los Angeles. He is board certified by the California Medical Board of Examiners and the American Board of Orthopedic Surgery. Dr. Kabaei is considered an expert in the treatment of patients with orthopedic trauma and complex joint problems from arthritis, previous trauma, infection, and childhood deformities. Additionally, he has specialized training in robotic hip and knee surgery and is an associate at DOCS Orthopedic Hospital, Cedars-Sinai Medical Center and Providence St. Johns in Santa Monica. His cutting-edge practice, Robotic Hip and Knee Replacement LA, is located at 8436 West 3rd Street Suite 800 in Los Angeles.

For more information about Robotic Hip and Knee Replacement LA or to schedule a consultation with Dr. Farzin Kabaei, please call (310) 792-9300 and visit http://www.robotichipandkneereplacementla.com.

Share article on social media or email:

Memorial Cardiac and Vascular Institute Utilizes New Monitoring Technologies to Benefit Heart Failure Patients


Dr. Iani Patsias is an advanced heart failure and transplant cardiologist within the Memorial Healthcare System (Hollywood, FL).

“As with any new technology, we will need to balance risk vs. benefit and apply technology that is meaningful to patient care. With new sensor technology will come a huge amount of new data.”- Iani Patsias, MD, FACC, Advanced Heart Failure and Transplant Cardiologist.

Technology is continuously evolving, and so is the approach taken by transplant cardiologists at Memorial Cardiac and Vascular Institute to using newer monitoring technologies with heart failure patients.

There are a number of devices that track physiological data that can be either implanted or worn. Each of these approaches has its own caveats, and advance heart failure cardiologists have to balance risk vs. benefit, especially if implanting a sensor through an invasive procedure.

“The patient has to understand and perceive its benefit to comply with data collection and deliver the data to the treatment team to act and, more importantly, prevent an admission,” said Iani Patsias, MD, FACC, Advanced Heart Failure and Transplant Cardiologist.

Within implantable sensors, the only current FDA- approved device is the CardioMEMS (Abbott). It is a small (3.5x2x15mm) implantable sensor that is deployed after a right heart catheterization and lays on a descending branch of the pulmonary artery. It doesn’t require any charging and communicates with a pillow with an embedded receptor, transmitting pulmonary artery pressures via Wi-Fi. Memorial Cardiac and Vascular Institute has a dedicated team for remote monitoring of patients using the CardioMEMS device.

“We can trend pulmonary artery pressures in time and can detect a pattern out of normal. This would then trigger an intervention, for example, increasing diuretics, with a goal of preventing decompensated heart failure and an admission to the hospital,” said Dr. Patsias.

Overall, heart failure is a growing and daunting disease. Monitoring can greatly assist in improving patient outcomes and quality of life. At Memorial Cardiac and Vascular Institute, the advanced heart failure team has been involved in the development of newer sensor technologies, and it looks promising for patient care.

“As with any new technology, we will need to balance risk vs. benefit and apply technology that is meaningful to patient care. With new sensor technology will come a huge amount of new data. It will be interesting to see how AI plays a role in population health data management and predictive analysis of our heart failure patients,” Dr. Patsias said.

# # #

The Memorial Cardiac & Vascular Institute is a cardiovascular care leader, offering a wide array of services dedicated to the prevention, detection, and treatment of cardiovascular disease. Its multi-disciplinary specialists collaborate using sophisticated diagnostic equipment and facilities. Cardiovascular care outcomes are regularly reviewed by physician-review panels and nurses to ensure quality assurance that utilizes computerized data collection.

For more information on total heart care, visit them at mhs.net/services/cardiac-vascular.

Share article on social media or email:

The 11th Annual Lake Nona Impact Forum Returns to Address Health Innovation in the New Reality


Dr. Sanjay Gupta speaking at the 2022 Lake Nona Impact Forum in Lake Nona, Orlando, Florida.

“Since its inception 11 years ago, Lake Nona Impact Forum’s North Star is to inspire human potential through health and wellbeing innovation,” said Impact Forum Founder Gloria Caulfield. “Our long-term goal is to be an incubator that accelerates innovation and sparks global change.”

Founded to address global issues and make an impact on health innovation, the annual Lake Nona Impact Forum will unite the foremost global thought leaders in health, wellbeing, technology and business from March 8–10, 2023. The event will feature in-depth, collaborative discussions about health innovation in the new reality. With a list of notable thought leaders from across the health spectrum including Dr. Chelsea Clinton, Dr. Rachel Levine, Paul Stamets and Dr. Sanjay Gupta, the invite-only event is hosted annually in the visionary community of Lake Nona located in Orlando. A mecca for health and wellbeing innovation, Lake Nona is home to some of the nation’s top universities, hospitals and research institutions where internationally acclaimed healthcare experts have launched businesses and pioneered first-of-its-kind advancements in their fields.

During a time in which the $4.4 trillion health and wellness industry continues to prove its importance in everyday life, heightened by exponential innovation during and following the COVID-19 pandemic, the Lake Nona Impact Forum brings together hundreds of diverse leaders and experts committed to improving human health on a global scale with a mission of developing and discussing long-term strategies that will catalyze the industry worldwide.

Coinciding with and celebrating International Women’s Day (March 8), prolific leaders will be speaking about equity for women in business and featured prominently throughout the three-day event including CVS Health President and Chief Executive Officer Karen Lynch, who was recently named the most inspirational CEO on the Fortune 500 list; Harvard T.H. Chan School of Public Health Assistant Professor of Immunology and Infectious Disease Dr. Kizzmekia Corbett, whose NIH team co-designed the leading COVID-19 vaccine mRNA-1273; Academy Award winning actor Geena Davis; and Organamet Bio CEO Doris Taylor, among others.

Throughout the event, the Impact Forum will host some of the world’s most creative thinkers to engage in uncommon conversations for extraordinary times including a dynamic mix of government and policy leaders, physicians and healthcare pioneers, prolific academics, technology visionaries from Fortune 50 companies to the world’s most promising start-ups, professional athletes and entertainers, CEOs and C-Suite executives and more.

This year’s program will feature discussions on topics hugely relevant to today’s industry leaders, including climate change and public health, brain health, health equity for children and women, cancer prevention, food as medicine and more.

Among the dozens of conversations taking place throughout the event, a few of the key panel discussions will include:


  • Remarkable Women Leading Global Change: Championing female leaders responsible for breakthroughs in their industries, the panel features Dr. Chelsea Clinton, Vice Chair, Clinton Foundation and Vice Chair, Clinton Health Access Initiative; Lauren Bush Lauren, Founder and Chief Brand Officer, FEED; and Noor Sweid, Managing Partner, Global Ventures; moderated by Alyson Shontell, Editor-in-Chief and CCO, Fortune Media.
  • The Repercussions of Healthcare on Climate Change: Setting national policy and global standards around the decarbonization of healthcare will be discussed by Dr. Victor Dzau, President, National Academy of Medicine; Dr. Rachel Levine, Admiral, U.S. Public Health Service, Assistant Secretary for Health, U.S. Department of Health and Human Services; George Barrett, Founder, The Overtone Group; and Dr. Jonathan Perlin, President and CEO, The Joint Commission; moderated by returning speaker Juju Chang, Emmy® Award-winning Co-Anchor, ABC News’ “Nightline.”
  • Psychedelics: The Trip of Our Lifetime: From the world’s foremost researchers on psychedelic medicine, promising findings on profound mental health conditions in this category will be shared by Dr. Rick Doblin, Founder and Executive Director, MAPS – Multidisciplinary Association for Psychedelic Studies; Dr. Rachel Yehuda, Director, Center for Psychedelic Psychotherapy and Trauma Research, Icahn School of Medicine at Mount Sinai; Dr. Robin Carhart-Harris, Ralph Metzner Distinguished Professor, Neurology and Psychiatry and Director, Psychedelics Division, Neuroscape, The University of California San Francisco; Paul Stamets, Mycologist, Inventor, Author, Entrepreneur, Earthling; and returning speaker Dr. Deepak Chopra, Co-Founder, The Chopra Foundation; Chairman, Chopra Global.

Fittingly, Lake Nona Impact Forum takes place within the living lab of Lake Nona where the latest technologies and innovative solutions are tested in a real-world environment every day. Purposefully planned to support healthy living, Lake Nona epitomizes an ecosystem of wellbeing with a medically-integrated sports and performance center, vibrant public art program, robust events calendar and miles of trails and dozens of parks anchored by a preeminent health and life sciences cluster. Thanks to the Impact Forum and the community’s unique focus on health, Lake Nona has attracted some of the world’s leading health and life sciences companies including Johnson & Johnson, Fountain Life, Chopra Global and Chopra Foundation, Limitless Minds, Hughston Clinic, HCA Healthcare, GuideWell Innovation, the University of Central Florida, the U.S. Department of Veterans Affairs and more.

“Since its inception 11 years ago, Lake Nona Impact Forum’s North Star is to inspire human potential through health and wellbeing innovation,” said Lake Nona Impact Forum Founder Gloria Caulfield. “As the meaning of wellbeing has evolved so have the discussions and luminaries we host, from the effects of the healthcare sector on climate change to the potential benefits of psychedelic therapy for mental health. Our long-term goal is to be an incubator that accelerates health and wellbeing innovation and sparks global change needed for public health, health systems and beyond.”

Click here for more details on all 2023 Impact Forum speakers and panelists.

The 2023 Lake Nona Impact Forum is presented by KPMG. Additional event supporters include Verizon, Fortune, Worth, Akkad Holdings, Chopra Foundation, GuideWell Innovation, AdventHealth, Citibank, Edyth Bush Charitable Foundation, Fountain Life, HCA Healthcare, Hughston Clinic, Integrated Wellness Partners, Leviton, Maximus, Microsoft, Garcia Stromberg, Myndstream, Labcorp and the Harvard T.H. Chan School of Public Health.

To learn more about the Impact Forum, visit http://www.LakeNonaImpactForum.org. Follow along with the Impact Forum on LinkedIn, Twitter and Instagram. You can also join the conversation online using the hashtag #LNIF23.

###

About Lake Nona Impact Forum:

For the past decade, Lake Nona has hosted a bespoke event, convening extraordinary health and innovation leaders at the annual Lake Nona Impact Forum. The Impact Forum has established a world class and intimate environment where C-Suite executives, prolific entrepreneurs, technology mavericks, health system/health plan CEOs, investors, and wellness experts can have stimulating, important conversations. The Impact Forum content is curated by a National Advisory Board comprised of world-renowned thought leaders from business, academia, government, the arts and industry who are heading the search for creative, innovative health and wellness solutions. This private health innovation retreat is reserved for 400 hand-selected delegates who can contribute, inspire and make changes to health.

For more information, visit http://www.LakeNonaImpactForum.org.

About Lake Nona:

Planned and developed by the Tavistock Group, Lake Nona is one of the fastest growing and most innovative communities in America. Located in Orlando, Florida, the 17-square-mile community has established a new standard of living for its residents with groundbreaking initiatives around technology, mobility, and wellbeing. Lake Nona is located contiguous to Orlando International Airport in the most visited destination in the U.S. The smart and connected community’s advanced infrastructure and commitment to collaboration has drawn visionary companies and entrepreneurs from across the globe to join its living lab environment accelerating economic growth and opportunity across health and life sciences, education, hospitality, and sports and performance. Lake Nona’s attractive business ecosystem is enhanced by a thriving cultural landscape defined by iconic architecture and engaging public art installations, miles of trails and walkable green spaces, weekly signature events, shopping, dining and entertainment options set amongst Central Florida’s beautiful natural landscape and year-round sunshine.

For more information, visit http://www.lakenona.com.